Selected abstracts of the Liver Cancer Summit 2022 of EASL
Note sull'episodio
In this podcast, Alejandro Forner summarised and commented some selected abstracts at the EASL Liver Cancer Summit 2022.
The following abstracts will be discussed:
1. Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study. Finn R, et al. Liver Cancer Summit 2022 OS-55
2. Efficacy of combination therapy with lenvatinib, programmed cell death 1 inhibitors and transarterial therapy: a propensity score-matching cohort study. Wei Lu, et al. Liver Cancer Summit 2022 PO-119
3. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study.Thomas Talbot, et al. Liver Cancer Summit 2022 PO-128
4. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma. Elia Gigante et al. Liver Cancer Summit 2022 PO-148
5. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with advanced hepatocellular carcinoma: A real-world, multicentre, retrospective study. Guohong Han et al. Liver Cancer Summit 2022 PO-220
6. Liver transplantation for combined hepatocellular-cholangiocarcinoma: An analysis of the European Liver Transplant Registry. Marco Claasen et al. Liver Cancer Summit 2022 PO-308
7. Liver transplantation for fibrolamellar hepatocellular carcinoma: An analysis of the European Liver Transplant Registry. Marco Claasen et al. Liver Cancer Summit 2022 PO-313